Ellohay everyay odybay!

Oesday anyay oneay antway otay peaksay inay igpay atinlay onay kypesay

Ellohay uysgay eway areay erryvay uckylay eway ancay alktay igpay atinlay ontday ayay hincktay?

Post has attachment

Ihay! Iway ovelay igpay atinlay. Owhay elseway oveslay erehay igpay atinlay?

Post has attachment

corpdev@ctiseattle.com Partnering with CTI
As an emerging commercial-stage biopharmaceutical company, collaboration remains at the core of our DNA. We welcome inquiries from highly qualified partners who can broaden and accelerate clinical trial development and potential commercialization of our product candidates. A partner will generate significant non-equity based operating capital, supplement our own internal expertise and provide us with access to the marketing, sales and distribution capabilities of our collaborators in specific territories.
A core element of our corporate strategy is to identify and acquire additional pipeline opportunities. Our current pipeline is the result of licensing and acquiring assets that we believe to be undervalued opportunities. We plan to continue to be opportunistic in seeking additional product candidates, and welcome high-quality drug candidates that offer the potential to advance the care of people affected by hematological malignancies and solid tumors.
Our scientific, regulatory and commercial expertise, combined with our ability to be nimble and open to creative collaboration structures, makes us an ideal partner for organizations that share our focus on hematology / oncology, innovation and commitment to improving the lives of patients.

Post has attachment

Post has attachment
Tweet #brending  
Pig Latin Tweet #brending
5 Photos - View album

Post has attachment
Wait while more posts are being loaded